Rapid and Sensitive Detection of Breast Cancer Cells in Patient Blood with Nuclease-Activated Probe Technology

A challenge for circulating tumor cell (CTC)-based diagnostics is the development of simple and inexpensive methods that reliably detect the diverse cells that make up CTCs. CTC-derived nucleases are one category of proteins that could be exploited to meet this challenge. Advantages of nucleases as CTC biomarkers include: (1) their elevated expression in many cancer cells, including cells implicated in metastasis that have undergone epithelial-to-mesenchymal transition; and (2) their enzymatic activity, which can be exploited for signal amplification in detection methods. Here, we describe a diagnostic assay based on quenched fluorescent nucleic acid probes that detect breast cancer CTCs via their nuclease activity. This assay exhibited robust performance in distinguishing breast cancer patients from healthy controls, and it is rapid, inexpensive, and easy to implement in most clinical labs. Given its broad applicability, this technology has the potential to have a substantive impact on the diagnosis and treatment of many cancers.

[1]  E. Madrigal-Bujaidar,et al.  Genetic expression profiles and chromosomal alterations in sporadic breast cancer in Mexican women. , 2006, Cancer genetics and cytogenetics.

[2]  T. Fehm,et al.  EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer , 2015, PloS one.

[3]  M. Daidone,et al.  Gene expression profiling of circulating tumor cells in breast cancer. , 2015, Clinical chemistry.

[4]  S. Digumarthy,et al.  Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.

[5]  B. Lim,et al.  Enrichment, detection and clinical significance of circulating tumor cells. , 2013, Lab on a chip.

[6]  P. Giangrande,et al.  Oligonucleotide aptamers: A next-generation technology for the capture and detection of circulating tumor cells. , 2016, Methods.

[7]  G. T. Budd,et al.  Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival , 2006, Clinical Cancer Research.

[8]  K. Pantel,et al.  Detection methods of circulating tumor cells. , 2012, Journal of thoracic disease.

[9]  W. Choi,et al.  Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer , 2016, Oncotarget.

[10]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[11]  M. Bjørås,et al.  Loss of Neil3, the major DNA glycosylase activity for removal of hydantoins in single stranded DNA, reduces cellular proliferation and sensitizes cells to genotoxic stress. , 2013, Biochimica et biophysica acta.

[12]  Cha-Mei Tang,et al.  Cytometric characterization of Circulating Tumor Cells Captured by microfiltration and their correlation to the cellsearch® CTC test , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[13]  Shana O Kelley,et al.  Beyond the Capture of Circulating Tumor Cells: Next-Generation Devices and Materials. , 2016, Angewandte Chemie.

[14]  S. Sleijfer,et al.  Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment? , 2015, Cancer treatment reviews.

[15]  K. Pantel,et al.  Challenges in circulating tumour cell research , 2014, Nature Reviews Cancer.

[16]  Mieke Schutte,et al.  Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells , 2009, Journal of the National Cancer Institute.

[17]  L. Zorzino,et al.  Prognostic value of circulating tumor cells in primary and metastatic breast cancer , 2012, Expert review of anticancer therapy.

[18]  Tanja Fehm,et al.  Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance , 2008, Breast Cancer Research.

[19]  Hyeun Joong Yoon,et al.  Emerging Role of Nanomaterials in Circulating Tumor Cell Isolation and Analysis , 2014, ACS nano.

[20]  Wen Tan,et al.  Overexpression and Hypomethylation of Flap Endonuclease 1 Gene in Breast and Other Cancers , 2008, Molecular Cancer Research.

[21]  Yasset Perez-Riverol,et al.  Making proteomics data accessible and reusable: Current state of proteomics databases and repositories , 2015, Proteomics.

[22]  E. Lianidou,et al.  The Role of CTCs as Tumor Biomarkers. , 2015, Advances in experimental medicine and biology.

[23]  Wei Yang,et al.  Nucleases: diversity of structure, function and mechanism , 2010, Quarterly Reviews of Biophysics.

[24]  C. Levy,et al.  Elevated ribonuclease activity in the thymus and white blood cells of genetically cancer prone mice , 1975, The Journal of experimental medicine.

[25]  Yan Zhang,et al.  Capturing Cancer: Emerging Microfluidic Technologies for the Capture and Characterization of Circulating Tumor Cells. , 2015, Small.

[26]  H. Yao,et al.  Potentiated DNA Damage Response in Circulating Breast Tumor Cells Confers Resistance to Chemotherapy* , 2015, The Journal of Biological Chemistry.

[27]  David A Hanauer,et al.  Bioinformatics approaches in the study of cancer. , 2007, Current molecular medicine.

[28]  Giovanna Bises,et al.  Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients , 2011, Acta oncologica.

[29]  Chia-Wen Tsai,et al.  Association of genetic polymorphisms of EXO1 gene with risk of breast cancer in Taiwan. , 2009, Anticancer research.

[30]  S. Sleijfer,et al.  Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy , 2014, Molecular Cancer Therapeutics.

[31]  Rebecca L. Siegel Mph,et al.  Cancer statistics, 2016 , 2016 .

[32]  T. Fehm,et al.  Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. , 2014, The Lancet. Oncology.

[33]  H. Iwata,et al.  Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer , 2017, Breast Cancer Research and Treatment.

[34]  Stefan Sleijfer,et al.  Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. , 2009, Cancer treatment reviews.

[35]  P. Heusser,et al.  Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies , 2012, BMC Cancer.

[36]  Rajan P Kulkarni,et al.  Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology , 2016, Oncotarget.

[37]  Fumihiro Tanaka,et al.  EpCAM-independent capture of circulating tumor cells with a 'universal CTC-chip'. , 2017, Oncology reports.

[38]  Ewan Birney,et al.  Databases and tools for browsing genomes. , 2002, Annual review of genomics and human genetics.

[39]  Klaus Pantel,et al.  [The circulating tumor cells: liquid biopsy of cancer]. , 2014, Klinicheskaia laboratornaia diagnostika.

[40]  E. Louis,et al.  Rif1 and Exo1 regulate the genomic instability following telomere losses , 2016, Aging cell.

[41]  Z. Bartosova,et al.  Nucleases in homologous recombination as targets for cancer therapy , 2014, FEBS letters.

[42]  Chen Huang,et al.  Comparison of analytic performances of Cellsearch and iFISH approach in detecting circulating tumor cells , 2015, Oncotarget.

[43]  T. Friedlander,et al.  Looking back, to the future of circulating tumor cells. , 2014, Pharmacology & therapeutics.

[44]  Qi-En Wang.  DNA damage responses in cancer stem cells: Implications for cancer therapeutic strategies. , 2015, World journal of biological chemistry.

[45]  L. Krejci,et al.  Cancer TARGETases: DSB repair as a pharmacological target. , 2016, Pharmacology & therapeutics.

[46]  A. Sokolenko,et al.  Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients. , 2015, Cancer letters.

[47]  S. Stewart,et al.  DNA2 and EXO1 in replication-coupled, homology-directed repair and in the interplay between HDR and the FA/BRCA network , 2012, Cell cycle.

[48]  M. Bartucci,et al.  DNA Damage Repair Pathways in Cancer Stem Cells , 2012, Molecular Cancer Therapeutics.

[49]  R. Rosell,et al.  Relevance of molecular characterization of circulating tumor cells in breast cancer in the era of targeted therapies , 2013, Expert review of molecular diagnostics.

[50]  Alison Stopeck,et al.  Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  D. Thedens,et al.  Non-invasive Imaging of Staphylococcus aureus Infections with a Nuclease-Activated Probe , 2013, Nature Medicine.

[52]  Zihui Xu,et al.  Curcumin inhibits proliferation of breast cancer cells through Nrf2-mediated down-regulation of Fen1 expression , 2014, The Journal of Steroid Biochemistry and Molecular Biology.

[53]  K. Pantel,et al.  Heterogeneous PSMA expression on circulating tumor cells - a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer , 2016, Oncotarget.

[54]  J. McNamara,et al.  Rapid, Culture-Free Detection of Staphylococcus aureus Bacteremia , 2016, PloS one.

[55]  J. McNamara,et al.  Degradation of nuclease-stabilized RNA oligonucleotides in Mycoplasma-contaminated cell culture media. , 2012, Nucleic acid therapeutics.

[56]  Nguyen Ngoc Hoa,et al.  BRCA1 and CtIP Are Both Required to Recruit Dna2 at Double-Strand Breaks in Homologous Recombination , 2015, PloS one.

[57]  Kazunori Hoshino,et al.  Multiscale immunomagnetic enrichment of circulating tumor cells: from tubes to microchips. , 2014, Lab on a chip.

[58]  M. Mardiney,et al.  Abnormal profile of human nucleolytic activity as a test for cancer. , 1975, Journal of the National Cancer Institute.

[59]  Kalyan Handique,et al.  Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples , 2016, PloS one.

[60]  Ruud H. Brakenhoff,et al.  Detection, clinical relevance and specific biological properties of disseminating tumour cells , 2008, Nature Reviews Cancer.

[61]  C. Levy,et al.  Alterations in ribonuclease activities in the plasma, spleen, and thymus of tumor-bearing mice. , 1975, Cancer research.

[62]  I. Tinhofer,et al.  Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition , 2012, BMC Cancer.

[63]  Youli Zu,et al.  Detecting Circulating Tumor Cells: Current Challenges and New Trends , 2013, Theranostics.

[64]  P. Fisher,et al.  Role of the staphylococcal nuclease and tudor domain containing 1 in oncogenesis (Review) , 2014, International journal of oncology.

[65]  S. Krobitsch,et al.  Effects of EpCAM overexpression on human breast cancer cell lines , 2011, BMC Cancer.

[66]  M. Daidone,et al.  Did Circulating Tumor Cells Tell us all they Could? The Missed Circulating Tumor Cell Message in Breast Cancer , 2015, The International journal of biological markers.

[67]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[68]  Yibin Kang,et al.  Identification of Staphylococcal Nuclease Domain-containing 1 (SND1) as a Metadherin-interacting Protein with Metastasis-promoting Functions* , 2011, The Journal of Biological Chemistry.